Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Moderna: A Stock to Watch or a Risky Bet?
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA
Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Arbutus Biopharma: Moderna Validates My IP Bull Case
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna wins EU contract for RSV vaccine supply
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
Moderna Appoints Michael McDonnell to Board of Directors
Moderna Stock Is Soaring. Is It Too Late to Buy?
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More